COMPANY PROFILE

Anngeen Technologies

Explore full profile

One of the first domestic practitioners to transform gene sequencing technology into clinical applications

Dongcheng District, ChinaFounded 2014Health Tech & Medtech

Valuation $50–100M Last recorded · 2020

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Anngeen Technologies

Anngeen Technologies, founded in 2017, operates within the biotechnology sector with a specific focus on genetic sequencing and diagnostics. The company is a developer and researcher of high-throughput gene sequencing technology. Its core business involves creating comprehensive solutions for the detection and diagnosis of genetic diseases, tumors, and cardiovascular conditions.

Anngeen serves medical facilities by providing them with tools that combine high-throughput sequencing with advanced bioinformatics analysis. This enables healthcare providers to improve their diagnostic capabilities in oncology and genetic disease detection. The company's business model appears to be centered on providing these specialized diagnostic products and services directly to the healthcare industry. Anngeen is a privately held, venture capital-backed company headquartered in Beijing, China.

The firm has successfully navigated early-stage funding rounds, securing a Series A investment in July 2018 and a subsequent Series B round of $14.3 million in January 2020. Investors in the company include SAIC Capital China and Sinovation Ventures.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Dongcheng District, China
Open positions: None listed
Dealroom signal: 23.3/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Genetics and genomics, Health Diagnostics, Hard Tech, DT and LS, science-based
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Feb 2020	$14M	$56M	Undisclosed	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Anngeen Technologies website traffic

Latest recorded traffic for Anngeen Technologies is 150 monthly website visits, down 67.4% over the last three months.

Latest monthly visits150 3-month web change-67.4%

Monthly website visitsMar 2020–Apr 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STShenzhen Letu Precision Medical TechnologyPioneering molecular diagnostics for oncology, reproductive health, and overall wellbeing in China	Ningbo, China	Operational	—	$138M	$550M
AQAqtualProviding advanced precision medicine products in the costliest disease areas	Hayward, United States	Operational
BOBerry OncologyGenomic testing and early screening for cancer	Fuzhou City, China	Operational
AGAres GeneticsWholly owned subsidiary of Curetis GmbH, a developer of next-generation molecular diagnostic solutions for infectious diseases	Vienna, Austria	Operational
LYLynsightMedical devices company committed to reducing cancer mortality rates with a simple diagnostic method that reliably detects an inherited cancer-causing condition prior to cancer	Helsinki, Finland	Operational
ATADmit TherapeuticsEpigenetic blood test for early Alzheimer's prognosis	Esplugues de Llobregat, Spain	Operational
BIBiofidelityRapid genomic biomarker detection for precision oncology	Cambridge, United Kingdom	Operational
LHLucira HealthIVD, Consumer Health, Disposable Testing	Emeryville, United States	Acquired